Kristen Riemenschneider's practice focuses on the broad range of legal issues facing biotechnology and pharmaceutical companies. Her experience includes negotiating agreements for the research, development, and commercialization of intellectual property and technology, including license and collaboration arrangements, clinical trial agreements, materials transfer agreements, sponsored research agreements, and manufacturing and supply arrangements; counseling with respect to the Bayh-Dole Act and the scope of protection afforded federal contractors under 28 U.S.C. s 1498; and negotiating intellectual property-centric agreements with the US government, including Cooperative Research and Development Agreements (CRADAs), grants, Technology Investment Agreements (TIAs), and Other Transactions Authority agreements (OTAs). Ms. Riemenschneider is a registered patent attorney.
- Novartis, in the negotiation of license and supply agreements with Spark Therapeutics for ex-US development and commercialization of Luxturna, the first approved gene therapy for an inherited disease. The transaction reflected a deal value of $170 million in achievable milestones as well as royalties.
- Insmed Incorporated, in the negotiation of a license and collaboration agreement with AstraZeneca regarding an early-stage respiratory drug. The transaction reflected a deal value of $150 million in achievable milestones and double-digit royalties.
- Idera Pharmaceuticals, in the negotiation of a license and collaboration agreement with GSK regarding the modulation of gene targets. The transaction reflected a deal value of 100 million.
- OPKO Health, in a license and development agreement with Pfizer for a long-acting human growth hormone (hGH-CTP) for adults and children. The deal terms included a $295 million upfront payment, an additional $270 million in milestones, and royalties and a profit share.
- Temptime Corporation, in the negotiation of a complex patent license from Freshpoint Quality Assurance Ltd., pertaining to time/temperature indicators for use in the monitoring of human vaccines.
- ADC Therapeutics, in the negotiation of various commercial arrangements pertaining to its antibody drug conjugate programs, including a license and collaboration agreement with MedImmune for two of ADC Therapeutics' antibody drug conjugate programs.
- Aduro BioTech, Inc., in the negotiation of various commercial arrangements pertaining to ongoing clinical trials.
- Bayer Consumer Care, in the sale of rights to ATX-101 to Kythera Biopharmaceuticals.
- Bruin Biometrics, Inc., in the negotiation various commercial arrangements pertaining to ongoing clinical trials.
- Spirogen, in its sale to MedImmune, for $200 million in cash and deferred consideration of up to $240 million.
- Sequella, in connection with a license and development agreement relating to its tuberculosis product to Maxwell Biotech for development and sale in Russia.
- JD, University of Virginia School of Law
- BSEE, Electrical Engineering, University of Virginia
- District of Columbia
- US Patent and Trademark Office
- United States Court of Federal Claims, The Honorable Francis Allegra
Member, Programs Committee, Women in Technology (WIT)
Vice Chair, Intellectual Property Committee, ABA Public Contract Law Section
Member, ABA Science & Technology Law Section
Member, ABA Intellectual Property Law Section
Member, National Defense Industrial Association (NDIA)
Extensive pro bono work, including representing individuals in civil disputes and in seeking public assistance, and representing organizations in corporate formation, obtaining tax-exempt status, and various commercial transactions